Esperion (Nasdaq: ESPR), a pharmaceutical company who recently announced the U.S. FDA approval of expanded indications for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet to include cardiovascular risk reduction and LDL cholesterol lowering in primary and secondary prevention patients, regardless of statin use, visits the Nasdaq MarketSite in Times Square. In honor of these recent FDA approvals, Sheldon Koenig, President & CEO, rings the Opening Bell.